“The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months among patients treated with second-generation drug-eluting stents (DES).”
Visit Website“Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) in combination with medical therapy had better health outcomes.”
Visit Website“Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk.”
Visit Website“The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow FFR-CT Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD).”
Visit Website“Biotronik’s Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during the 2017 Transcatheter Cardiovascular Therapeutics Annual Conference (TCT 2017), Oct. 29-Nov. 2 in Denver.”
Visit Website“Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October, based on website analytics of the month’s 163,117 pageviews:”
Visit Website“Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System.”
Visit Website“Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority.”
Visit Website“The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR.”
Visit Website“Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure.”
Visit Website